X4 Pharmaceuticals

Update in progress

XFOR (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

X4 Pharmaceuticals is a biopharma company focused on researching, developing, and commercializing therapies for rare immune-related diseases. Its lead asset, XOLREMDI, is an oral CXCR4 antagonist in phase 3 for conditions including warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It licenses XOLREMDI to Abbisko for Greater China; mavorixafor to Norgine for Europe, Australia, and New Zealand; and works with Genzyme on CXCR4 programs. Based in Boston.

Company score

Sentiment: 0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.36; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive